SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3753-3760. Prepublished online as a Blood First Edition Paper on January 12, 2006; DOI 10.1182/blood-2004-03-0930. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-0930v1 107/9/3753    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mintz, P. D. Articles by Corash, L. Search for Related Content PubMed PubMed Citation Articles by Mintz, P. D. Articles by Corash, L. Related Collections Hemostasis, Thrombosis, and Vascular Biology Transfusion Medicine Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSFUSION MEDICINE Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease Paul D. Mintz, Nathan M. Bass, Lawrence D. Petz, Randolph Steadman, Michael Streiff, Jeffery McCullough, Sandra Burks, David Wages, Sally Van Doren, and Laurence Corash From the Departments of Pathology and Internal Medicine, University of Virginia, Charlottesville; Department of Medicine, University of California, San Francisco; Department of Pathology and Laboratory Medicine and Department of Anesthesiology, University of California, Los Angeles; Department of Medicine, Johns Hopkins University, Baltimore, MD; Departments of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis; Department of Surgery, University of Virginia, Charlottesville; and Cerus, Concord, CA. An ex vivo photochemical treatment (PCT) process was developed to inactivate pathogens in fresh frozen plasma (PCT-FFP). A prospective, controlled, double-blinded, randomized study was conducted to evaluate the efficacy and safety of PCT-FFP compared with conventional FFP (C-FFP). Patients (n = 121) with acquired coagulopathy, largely due to liver disease, including hepatic transplantation, were transfused with either PCT-FFP or C-FFP for up to 7 days. Primary end points were changes in the prothrombin time (PT) and the partial thromboplastin time (PTT) in response to the first FFP transfusion. Secondary analyses compared changes in the PT and the PTT, factor VII levels, clinical hemostasis, blood component usage, and safety following FFP transfusions for up to 7 days. Following the first transfusion, correction in the PT and PTT adjusted for FFP dose and patient weight was not different. Changes in the PT were equivalent between treatment groups (P = .002 by noninferiority). Equivalence was not demonstrated for changes in the PTT. Following multiple transfusions, correction of the PT and the PTT was similar between groups. No differences were observed in use of blood components, clinical hemostasis, or safety. These results suggest PCT-FFP supported hemostasis in the treatment of acquired coagulopathy similarly to conventional FFP. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. J. Stanworth The Evidence-Based Use of FFP and Cryoprecipitate for Abnormalities of Coagulation Tests and Clinical Coagulopathy Hematology, January 1, 2007; 2007(1): 179 - 186. [Abstract] [Full Text] [PDF] J.-P. Cazenave, H. Isola, M.-L. Wiesel, D. Kientz, M. Laforet, M. Slaedts, L. Pinkoski, Y. Singh, and L. Corash Coagulation Factors in Therapeutic Apheresis Plasma Held for 18 Hours at Ambient Temperature Prior to Pathogen Inactivation (INTERCEPTTM). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 940 - 940. [Abstract] [Full Text] [PDF] J.-P. Cazenave, H. Isola, M.-L. Wiesel, D. Kientz, M. Laforet, L. Pinkoski, Y. Singh, and L. Corash Coagulation Factor Activity in Therapeutic Plasma Prepared from Whole Blood with Pathogen Inactivation (INTERCEPTTM) Treatment. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 4149 - 4149. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020